ReviewAging clinical and experimental research2025
Influenza vaccination in older people: a geriatrician's perspective.
Review in Aging clinical and experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Seasonal influenza vaccination uptake among older adults in Yerevan, Armenia.BMC geriatrics · 2026Article
- Infectious diseases, infection control, vaccines and long-term care: an European interdisciplinary Council on ageing consensus document.Aging clinical and experimental research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Influenza poses a significant threat to older adults, exacerbated by age-related immune decline and the high prevalence of chronic conditions. Despite being the most effective preventive measure, influenza vaccination rates among this population remain alarmingly low, with Italy and Europe failing to meet the World Health Organization’s target of 75% coverage for individuals aged 65 and over. This review, informed by a geriatric conference in Enna, Sicily, examines the epidemiology of influenza in older populations, the impact of frailty on vaccination, and specific considerations for patients with dementia and diabetes. High-dose (HD) and adjuvanted inactived vaccines emerge as vital tools, offering enhanced immunogenicity and efficacy tailored to the unique needs of older adults. Economic analyses underscore the high direct and indirect costs of influenza in older populations, advocating vaccination as a cost-effective intervention. The authors call for increased geriatrician advocacy, education of healthcare professionals, and tailored public health strategies to improve vaccine uptake, especially among frail individuals and those with dementia or diabetes. By addressing these gaps, influenza vaccination can significantly mitigate the clinical, economic, and social burdens of the disease in older adults. The review highlights barriers to vaccination, including healthcare workers’ hesitancy, misinformation, and logistical challenges in geriatric care settings. Enhanced vaccination strategies, particularly the use of HD vaccines, are shown to reduce hospitalizations, mortality, and healthcare costs. Furthermore, the integration of vaccination into life-course immunization policies is essential for minimizing disease burden and promoting healthy aging.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.